Identification

Name
Cilazapril
Accession Number
DB01340
Type
Small Molecule
Groups
Approved
Description

Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.

Structure
Thumb
Synonyms
  • Cilazapril
  • Cilazapril anhydrous
  • Cilazaprilum
External IDs
Ro 31-2848
Product Ingredients
IngredientUNIICASInChI Key
Cilazapril monohydrate19KW7PI29F92077-78-6JQRZBPFGBRIWSN-YOTVLOEGSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CilazaprilTablet1 mgOralSanis Health Inc2010-05-31Not applicableCanada
CilazaprilTablet1.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
CilazaprilTablet5 mgOralSanis Health Inc2010-05-312014-08-01Canada
CilazaprilTablet2.5 mgOralSanis Health Inc2010-05-31Not applicableCanada
CilazaprilTablet2.5 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
CilazaprilTablet5.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Co CilazaprilTablet5.0 mgOralCobalt Laboratories2007-02-06Not applicableCanada
Co CilazaprilTablet1.0 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Co CilazaprilTablet2.5 mgOralCobalt Laboratories2007-02-06Not applicableCanada
Dom-cilazaprilTablet2.5 mgOralDominion PharmacalNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cilazaprilTablet1 mgOralApotex Corporation2007-02-01Not applicableCanada
Apo-cilazaprilTablet2.5 mgOralApotex Corporation2007-02-01Not applicableCanada
Apo-cilazaprilTablet5 mgOralApotex Corporation2007-02-01Not applicableCanada
International/Other Brands
Dynorm (Roche) / Inhibace (Roche) / Inhibestril (Teva) / Vascace (Roche) / Zapril (Mylan) / Zobox (Hemofarm)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Apo-cilazapril/hctzCilazapril (5 mg) + Hydrochlorothiazide (12.5 mg)TabletOralApotex Corporation2006-08-23Not applicableCanada
Inhibace Plus - TabCilazapril (5 mg) + Hydrochlorothiazide (12.5 mg)TabletOralHoffmann La Roche1999-04-01Not applicableCanada
Novo-cilazapril/hctzCilazapril (5 mg) + Hydrochlorothiazide (12.5 mg)TabletOralTeva2009-03-30Not applicableCanada
Categories
UNII
8Q9454114Q
CAS number
88768-40-5
Weight
Average: 417.4986
Monoisotopic: 417.226371117
Chemical Formula
C22H31N3O5
InChI Key
HHHKFGXWKKUNCY-FHWLQOOXSA-N
InChI
InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
IUPAC Name
(1S,9S)-9-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxo-octahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CCCN2CCC[[email protected]](N2C1=O)C(O)=O

Pharmacology

Indication

Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.

Structured Indications
Pharmacodynamics

Cilazapril inhibits the production angiotensin II. By doing so, it decreases sodium and water reabsorption (via aldosterone) and it decreases vasoconstriction. The combined effect of this is a decrease in vascular resistance, and therefore, blood pressure. The absolute bioavailability of cilazaprilat after oral administration of cilazapril is 57% based on urinary recovery data. (The absolute bioavailability of cilazaprilat after oral administration of cilazaprilat is 19%.) Ingestion of food immediately before the administration of cilazapril reduces the average peak plasma concentration of cilazaprilat by 29%, delays the peak by one hour and reduces the bioavailability of cilazaprilat by 14%. These pharmacokinetic changes have little influence on plasma ACE inhibition.

Mechanism of action

Cilazapril is a pyridazine ACE inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Maximum plasma concentrations of cilazaprilat are reached within two hours after administration of cilazapril.

Volume of distribution
Not Available
Protein binding

Maximum ACE inhibition is greater than 90% after 1 to 5 mg cilazapril. Maximum ACE inhibition is 70 to 80% after 0.5 mg cilazapril. Dose proportionality is observed following the administration of 1 to 5 mg cilazapril. Apparent non-proportionality is observed at 0.5 mg reflective of the binding to ACE. The higher doses of cilazapril are associated with longer duration of maximum ACE inhibition.

Metabolism
Route of elimination

Cilazaprilat is eliminated unchanged by the kidneys. The total urinary recovery of cilazaprilat after intravenous administration of 2.5 mg is 91%.

Half life

Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.

Clearance

Total clearance is 12.3 L/h and renal clearance is 10.8 L/h. The total urinary recovery of cilazaprilat following the oral administration of 2.5 mg cilazapril is 52.6%.

Toxicity

Limited data are available with regard to overdosage in humans. The most likely manifestations are hypotension, which may be severe, hyperkalaemia, hyponatraemia and renal impairment with metabolic acidosis. Treatment should be mainly symptomatic and supportive.

Affected organisms
Not Available
Pathways
PathwayCategory
Cilazapril Metabolism PathwayDrug metabolism
Cilazapril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Cilazapril.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Cilazapril.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Cilazapril.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Acemetacin.Approved
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Cilazapril.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Adapalene.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Cilazapril.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Alclofenac.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Cilazapril.Approved, Investigational
AliskirenAliskiren may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Cilazapril.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Alminoprofen.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Cilazapril.Approved
AloxiprinAloxiprin may decrease the antihypertensive activities of Cilazapril.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Cilazapril.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Cilazapril.Approved, Withdrawn
AmbrisentanCilazapril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Cilazapril.Experimental, Investigational
AmifostineCilazapril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Cilazapril.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Cilazapril.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Cilazapril.Approved
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Cilazapril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Cilazapril.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Cilazapril.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Cilazapril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Cilazapril.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Cilazapril.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Cilazapril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Cilazapril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Cilazapril is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Andrographolide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Antipyrine.Approved
ApocyninThe risk or severity of adverse effects can be increased when Cilazapril is combined with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Cilazapril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Cilazapril.Approved
ApremilastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Apremilast.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Cilazapril.Approved, Withdrawn
ArdeparinArdeparin may increase the hyperkalemic activities of Cilazapril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Cilazapril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cilazapril.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Cilazapril.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Cilazapril.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Cilazapril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Cilazapril.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azapropazone.Withdrawn
AzathioprineCilazapril may increase the myelosuppressive activities of Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Cilazapril.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Cilazapril.Experimental
BarbitalBarbital may increase the hypotensive activities of Cilazapril.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Cilazapril.Approved
BemiparinBemiparin may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Cilazapril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Cilazapril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Cilazapril.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Benoxaprofen.Withdrawn
BenzydamineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Benzydamine.Approved
BepridilBepridil may increase the hypotensive activities of Cilazapril.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Cilazapril.Approved
BethanidineBethanidine may increase the hypotensive activities of Cilazapril.Approved
BevoniumThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bevonium.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Cilazapril.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Cilazapril.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Cilazapril.Approved
BoceprevirThe serum concentration of Cilazapril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Cilazapril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Cilazapril.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Cilazapril.Approved
BQ-123Cilazapril may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Cilazapril.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Cilazapril.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Cilazapril.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Cilazapril.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Cilazapril.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bucillamine.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bufexamac.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Cilazapril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Cilazapril.Approved, Investigational
BupranololCilazapril may increase the hypotensive activities of Bupranolol.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Cilazapril.Approved
CadralazineCadralazine may increase the hypotensive activities of Cilazapril.Experimental
CafedrineCilazapril may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Cilazapril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Cilazapril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Cilazapril.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Cilazapril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Cilazapril.Approved
CarbamazepineThe metabolism of Cilazapril can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Cilazapril.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Cilazapril.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Cilazapril.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Cilazapril.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Cilazapril.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Celecoxib.Approved, Investigational
CeliprololCilazapril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinCertoparin may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cilazapril.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Cilazapril.Investigational, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cilazapril.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Cilazapril.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Choline magnesium trisalicylate.Approved
CicletanineCilazapril may increase the hypotensive activities of Cicletanine.Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Cilazapril.Approved, Investigational
CiprofloxacinCilazapril may increase the arrhythmogenic activities of Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cilazapril.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Cilazapril.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Cilazapril.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Cilazapril.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Cilazapril.Approved
ClonixinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clonixin.Approved
CloranololCilazapril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Cilazapril.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Cilazapril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Cilazapril.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be decreased when it is combined with Cilazapril.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Cilazapril.Approved
CurcuminThe risk or severity of adverse effects can be increased when Cilazapril is combined with Curcumin.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilazapril.Approved
CyclopenthiazideCilazapril may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Cilazapril.Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Cilazapril is combined with D-Limonene.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Cilazapril.Approved
DalteparinDalteparin may increase the hyperkalemic activities of Cilazapril.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Cilazapril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Cilazapril.Approved, Investigational
DelaprilCilazapril may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Cilazapril.Approved
dersalazinedersalazine may decrease the antihypertensive activities of Cilazapril.Investigational
DeserpidineCilazapril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Cilazapril.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Cilazapril.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Cilazapril.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Cilazapril.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Cilazapril.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Cilazapril.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Cilazapril.Approved, Investigational
diethylnorspermineCilazapril may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Cilazapril.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Difenpiramide.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Cilazapril.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Cilazapril.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Cilazapril.Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Cilazapril.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Cilazapril.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Cilazapril.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Cilazapril.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Cilazapril.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Cilazapril.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Cilazapril.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Cilazapril.Approved, Investigational
DrospirenoneCilazapril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Droxicam.Approved
DuloxetineCilazapril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Duvelisib.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Cilazapril.Approved
E-6201The risk or severity of adverse effects can be increased when Cilazapril is combined with E-6201.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Cilazapril.Approved
EfonidipineCilazapril may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Cilazapril.Approved, Vet Approved
EnalaprilatCilazapril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Cilazapril.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Cilazapril.Approved, Investigational
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Cilazapril.Approved
EpanololCilazapril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Cilazapril is combined with Epirizole.Approved
EplerenoneEplerenone may increase the hyperkalemic activities of Cilazapril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Cilazapril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Cilazapril.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Cilazapril.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Cilazapril.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Cilazapril.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Cilazapril.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Cilazapril.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Cilazapril.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Cilazapril.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Cilazapril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Cilazapril.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cilazapril.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cilazapril.Approved
EtodolacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Cilazapril.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Evening primrose oil.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Cilazapril.Approved
exisulindThe risk or severity of adverse effects can be increased when Cilazapril is combined with exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Cilazapril.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Cilazapril.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fenoprofen.Approved
FentiazacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Feprazone.Experimental
Ferulic acidCilazapril may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Cilazapril.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Floctafenine.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flunoxaprofen.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Flurbiprofen.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Cilazapril.Experimental
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cilazapril.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Cilazapril.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Cilazapril.Approved, Vet Approved
GarlicThe serum concentration of Cilazapril can be decreased when it is combined with Garlic.Approved
GuacetisalGuacetisal may decrease the antihypertensive activities of Cilazapril.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Cilazapril.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Cilazapril.Approved
GuanazodineCilazapril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Cilazapril.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Cilazapril.Approved, Investigational
GuanoclorCilazapril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzCilazapril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanCilazapril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Cilazapril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Cilazapril.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may decrease the antihypertensive activities of Cilazapril.Experimental
HeparinHeparin may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
HexamethoniumCilazapril may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Cilazapril.Withdrawn
HexobarbitalHexobarbital may increase the hypotensive activities of Cilazapril.Approved
HigenamineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Cilazapril.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Cilazapril.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Cilazapril.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Cilazapril.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ibuproxam.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Cilazapril.Approved
IloprostIloprost may increase the hypotensive activities of Cilazapril.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Cilazapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Imidazole salicylate.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Cilazapril.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Cilazapril.Approved
IndenololCilazapril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Cilazapril.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Cilazapril.Experimental
IproclozideIproclozide may increase the hypotensive activities of Cilazapril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Cilazapril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Cilazapril.Approved, Investigational
IronThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cilazapril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cilazapril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Cilazapril.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Cilazapril.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Cilazapril.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Cilazapril.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Cilazapril.Approved
LacidipineCilazapril may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Cilazapril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Cilazapril.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Cilazapril.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Cilazapril.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Cilazapril.Approved, Investigational
LevodopaCilazapril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Cilazapril.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Cilazapril.Approved
LinsidomineCilazapril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Cilazapril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Cilazapril.Approved
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Cilazapril.Experimental
LofexidineCilazapril may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Cilazapril.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Cilazapril.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Lumiracoxib.Approved, Investigational
MacitentanCilazapril may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Magnesium salicylate.Approved
ManidipineCilazapril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Cilazapril.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Masoprocol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Cilazapril.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Cilazapril.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mefenamic acid.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Meloxicam.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Cilazapril.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Cilazapril.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Cilazapril is combined with Metamizole.Investigational, Withdrawn
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Cilazapril.Experimental
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Cilazapril.Approved
MethohexitalMethohexital may increase the hypotensive activities of Cilazapril.Approved
MethoserpidineCilazapril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Cilazapril.Approved
Methyl salicylateMethyl salicylate may decrease the antihypertensive activities of Cilazapril.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Cilazapril.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Cilazapril.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Cilazapril.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cilazapril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Cilazapril.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Cilazapril.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Cilazapril.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Cilazapril.Approved, Investigational
MetyrosineCilazapril may increase the hypotensive activities of Metyrosine.Approved
MibefradilCilazapril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Cilazapril.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Cilazapril.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Cilazapril.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Cilazapril.Investigational
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Cilazapril.Approved
MizoribineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Cilazapril.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Cilazapril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Cilazapril.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cilazapril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Cilazapril.Approved, Investigational
MuzolimineCilazapril may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Cilazapril.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Cilazapril.Approved
NadroparinNadroparin may increase the hyperkalemic activities of Cilazapril.Approved
NafamostatThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Naftifine.Approved
NaftopidilCilazapril may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Cilazapril.Approved
NaproxenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Naproxen.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Cilazapril.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Cilazapril.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Cilazapril.Approved
NicorandilNicorandil may increase the hypotensive activities of Cilazapril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Cilazapril.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Niflumic Acid.Approved
NiguldipineCilazapril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineCilazapril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Cilazapril.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Cilazapril.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Cilazapril.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Cilazapril.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Cilazapril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Cilazapril.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Cilazapril.Approved
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Cilazapril.Approved
ObinutuzumabCilazapril may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Cilazapril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Cilazapril.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Cilazapril.Investigational
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Cilazapril.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Orgotein.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxaprozin.Approved
OxprenololCilazapril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cilazapril.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Cilazapril.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Cilazapril.Approved
ParnaparinParnaparin may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Parthenolide.Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Cilazapril.Approved
PenbutololThe risk or severity of adverse effects can be increased when Cilazapril is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Cilazapril.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cilazapril.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Cilazapril.Approved
PethidineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Cilazapril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Cilazapril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Cilazapril.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Cilazapril.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cilazapril.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Cilazapril.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Cilazapril.Approved
PinacidilPinacidil may increase the hypotensive activities of Cilazapril.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Cilazapril.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Cilazapril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Cilazapril.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pirfenidone.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Cilazapril.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pirprofen.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Cilazapril.Withdrawn
Platelet Activating FactorCilazapril may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Cilazapril.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Cilazapril.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pranoprofen.Experimental, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Cilazapril.Approved
PregabalinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Cilazapril.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cilazapril.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Cilazapril.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Proquazone.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Cilazapril.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Cilazapril.Approved
PTC299The risk or severity of adverse effects can be increased when Cilazapril is combined with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Cilazapril.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Cilazapril.Approved, Investigational
QuinethazoneQuinethazone may increase the hypotensive activities of Cilazapril.Approved
QuinineQuinine may increase the hypotensive activities of Cilazapril.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Cilazapril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Cilazapril.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Cilazapril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cilazapril.Approved
RemikirenRemikiren may increase the hypotensive activities of Cilazapril.Approved
RescinnamineCilazapril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cilazapril.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Cilazapril is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinReviparin may increase the hyperkalemic activities of Cilazapril.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Cilazapril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Cilazapril.Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Cilazapril.Approved
RisperidoneCilazapril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabCilazapril may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Cilazapril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Cilazapril.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Cilazapril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Cilazapril.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Cilazapril.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salicylamide.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Cilazapril.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Cilazapril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Cilazapril.Investigational
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Cilazapril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Cilazapril.Approved, Investigational, Vet Approved
SelexipagCilazapril may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Cilazapril is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Cilazapril is combined with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cilazapril.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Cilazapril.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Cilazapril.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Cilazapril.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Cilazapril.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cilazapril.Approved, Investigational
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Cilazapril.Approved, Investigational
SitaxentanCilazapril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sodium aurothiomalate.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Cilazapril.Approved
Sodium phosphateCilazapril may increase the nephrotoxic activities of Sodium phosphate.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Cilazapril.Approved
SpiraprilCilazapril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Cilazapril.Approved
SRT501The risk or severity of adverse effects can be increased when Cilazapril is combined with SRT501.Investigational
St. John's WortThe metabolism of Cilazapril can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Cilazapril.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cilazapril.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sulindac.Approved
SuprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Cilazapril is combined with Suxibuzone.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Cilazapril.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cilazapril.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Cilazapril.Approved, Investigational
TalinololCilazapril may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Cilazapril.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Cilazapril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Cilazapril.Approved, Investigational
TemocaprilCilazapril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Cilazapril is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tenidap.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Cilazapril.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Teriflunomide.Approved
TerlipressinCilazapril may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineCilazapril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Cilazapril.Approved, Investigational, Withdrawn
TheodrenalineCilazapril may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Cilazapril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Cilazapril.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Cilazapril.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tiaprofenic acid.Approved
TiboloneCilazapril may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenCilazapril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Cilazapril.Approved
TinoridineThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tinoridine.Investigational
TinzaparinTinzaparin may increase the hyperkalemic activities of Cilazapril.Approved
TipranavirThe serum concentration of Cilazapril can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the hypotensive activities of Cilazapril.Approved
TolazolineTolazoline may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Cilazapril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tolmetin.Approved
TolonidineCilazapril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Cilazapril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Cilazapril.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Cilazapril.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Cilazapril.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Cilazapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cilazapril.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Cilazapril.Approved
TravoprostTravoprost may increase the hypotensive activities of Cilazapril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Cilazapril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Cilazapril.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Cilazapril.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Cilazapril.Approved
TribenosideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Tribenoside.Experimental
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Cilazapril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Cilazapril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Cilazapril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Cilazapril.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Cilazapril.Approved
TriptolideThe risk or severity of adverse effects can be increased when Cilazapril is combined with Triptolide.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Cilazapril.Approved
UdenafilUdenafil may increase the antihypertensive activities of Cilazapril.Approved, Investigational
UnoprostoneCilazapril may increase the hypotensive activities of Unoprostone.Approved
UrapidilUrapidil may increase the hypotensive activities of Cilazapril.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Cilazapril is combined with Valdecoxib.Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Cilazapril.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Cilazapril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Cilazapril.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Cilazapril.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Cilazapril.Approved, Investigational
VincamineCilazapril may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Cilazapril.Approved, Investigational
VinpocetineCilazapril may increase the hypotensive activities of Vinpocetine.Investigational
XipamideCilazapril may increase the hypotensive activities of Xipamide.Experimental
XylometazolineCilazapril may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Cilazapril.Approved, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Cilazapril.Approved
ZileutonThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilCilazapril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Cilazapril is combined with Zomepirac.Withdrawn
Food Interactions
  • Food decreases cilazapril absorption with no significant clinical impact.
  • Take without regard to meals.

References

Synthesis Reference

Attwood, M. R.; Hassall, C. H.; Kr�Hn, A.; Lawton, G.; Redshaw, S. (1986). "The design and synthesis of the Angiotensin Converting Enzyme inhibitor Cilazapril and related bicyclic compounds". Journal of the Chemical Society, Perkin Transactions 1: 1011. doi:10.1039/P19860001011

US20060293517
General References
  1. Fasanella d'Amore T, Bussien JP, Nussberger J, Waeber B, Turini GA, Brunner HR, Kler L, Francis RJ: Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol. 1987 Jan;9(1):26-31. [PubMed:2434790]
External Links
Human Metabolome Database
HMDB15433
KEGG Drug
D07699
PubChem Compound
56330
PubChem Substance
46505231
ChemSpider
50831
ChEBI
3698
ChEMBL
CHEMBL515606
Therapeutic Targets Database
DAP000912
PharmGKB
PA164748302
Drugs.com
Drugs.com Drug Page
Wikipedia
Cilazapril
ATC Codes
C09BA08 — Cilazapril and diureticsC09AA08 — Cilazapril
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
FDA label
Download (114 KB)
MSDS
Download (81.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableUnknown StatusTreatmentIgA Glomerulonephritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
TabletOral2.5 mg
TabletOral5 mg
TabletOral1 mg
TabletOral1.0 mg
TabletOral5.0 mg
Prices
Unit descriptionCostUnit
Inhibace 5 mg Tablet0.94USD tablet
Inhibace 2.5 mg Tablet0.81USD tablet
Inhibace 1 mg Tablet0.7USD tablet
Apo-Cilazapril 5 mg Tablet0.52USD tablet
Co Cilazapril 5 mg Tablet0.52USD tablet
Mylan-Cilazapril 5 mg Tablet0.52USD tablet
Novo-Cilazapril 5 mg Tablet0.52USD tablet
Pms-Cilazapril 5 mg Tablet0.52USD tablet
Apo-Cilazapril 2.5 mg Tablet0.45USD tablet
Co Cilazapril 2.5 mg Tablet0.45USD tablet
Mylan-Cilazapril 2.5 mg Tablet0.45USD tablet
Novo-Cilazapril 2.5 mg Tablet0.45USD tablet
Pms-Cilazapril 2.5 mg Tablet0.45USD tablet
Apo-Cilazapril 1 mg Tablet0.39USD tablet
Mylan-Cilazapril 1 mg Tablet0.39USD tablet
Novo-Cilazapril 1 mg Tablet0.39USD tablet
Pms-Cilazapril 1 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US20060293517No2004-03-082024-03-08Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)98 ºC with decomposition Not Available
water solubilityWater (25 ºC) 0.5 g/100 mL Not Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.06 mg/mLALOGPS
logP-0.2ALOGPS
logP-0.0079ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)5.35ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.18 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity110.56 m3·mol-1ChemAxon
Polarizability44.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier-0.9402
Caco-2 permeable-0.7698
P-glycoprotein substrateSubstrate0.8727
P-glycoprotein inhibitor IInhibitor0.7775
P-glycoprotein inhibitor IINon-inhibitor0.8788
Renal organic cation transporterNon-inhibitor0.8318
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.8283
CYP450 3A4 substrateSubstrate0.5396
CYP450 1A2 substrateNon-inhibitor0.882
CYP450 2C9 inhibitorNon-inhibitor0.7804
CYP450 2D6 inhibitorNon-inhibitor0.7503
CYP450 2C19 inhibitorNon-inhibitor0.816
CYP450 3A4 inhibitorNon-inhibitor0.8201
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8376
Ames testNon AMES toxic0.6023
CarcinogenicityNon-carcinogens0.9028
BiodegradationNot ready biodegradable0.9942
Rat acute toxicity2.3700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9311
hERG inhibition (predictor II)Inhibitor0.6303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Alpha amino acid esters / 1,2-diazepanes / Fatty acid esters / Aralkylamines / Pyridazines and derivatives / Dicarboxylic acids and derivatives / Diazinanes / Benzene and substituted derivatives / Amino acids / Carboxylic acid hydrazides
show 8 more
Substituents
Alpha-dipeptide / Alpha-amino acid ester / Alpha-amino acid or derivatives / 1,2-diazepane / Fatty acid ester / Diazepane / Aralkylamine / Dicarboxylic acid or derivatives / 1,2-diazinane / Pyridazine
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, Teragaki M, Akioka K, Iwao H, Yoshikawa J: Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension. 1999 Apr;33(4):961-8. [PubMed:10205231]
  2. Kihara M, Mitsui MK, Mitsui Y, Okuda K, Nakasaka Y, Takahashi M, Schmelzer JD: Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve. 1999 Jul;22(7):920-5. [PubMed:10398211]
  3. Mervaala E, Dehmel B, Gross V, Lippoldt A, Bohlender J, Milia AF, Ganten D, Luft FC: Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol. 1999 Aug;10(8):1669-80. [PubMed:10446934]
  4. Rosendorff C, Patton J, Radford HM, Kalliatakis B: Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S105-9. [PubMed:1382157]
  5. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, Lacour B, Grunfeld JP: Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S25-7. [PubMed:1382161]
  6. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B: Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18. [PubMed:18423812]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 30, 2007 12:09 / Updated on November 19, 2017 20:34